IPSC - Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

2024-06-20 11:07:05 ET

Summary

• Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients.
• The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029.
• Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024.
• A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses.

Century Therapeutics, Inc. ( IPSC ) is a very interesting cell therapy biotech, especially with the accomplishments it has been able to make thus far. That's because it released positive interim data as a poster presentation at the American Society of Clinical Oncology [ASCO] Annual Meeting, which was held May 31 - June 4th, 2024. In particular, it tested the use of CNTY-101 as an induced pluripotent stem cell [iPSC] derived natural killer [NK] drug for the treatment of patients with relapsed or refractory non-Hodgkin lymphoma [NHL], in the ongoing phase 1 ELiPSE-1 study....

For further details see: